Using genetic engineering, immunotherapies mobilize the body’s own cells against cancer. This revolutionary therapy has demonstrated remarkable curative potential, but comes with a big price tag and many complex technical challenges. Health-care providers, governments and industry are working on solutions that will make this therapy widely available. With the first immunotherapies having won regulatory approval in the United States, we are slowly making progress. What does this mean for Canada? What are the key challenges we need to address to bring immunotherapy to patients here at home?
The discussion included:
– Michael May, PhD, President & CEO, CCRM (Moderator)
– Donna Wall, MD, Section Head – Blood and Marrow Transplant/Cell Therapy Program, Division of Haematology/Oncology, The Hospital for Sick Children
– Justin Shakespeare, Executive Director, Oncology Business Unit, Amgen
– Patrick Bedford, Senior Manager, Clinical Translation and Regulatory Affairs, CCRM
– Aaron Dulgar-Tulloch, PhD, Director of BridGE, GE Healthcare Cell Therapy
This event took place during Toronto Health Innovation Week 2018, on April 11, 2018.
